Prokidney (PROK) Cash from Investing Activities (2021 - 2026)
Prokidney's (PROK) quarterly Cash from Investing Activities came in at $34.8 million in Q1 2026, up 23.11% year-on-year from $28.3 million in Q1 2025, and up 23.97% on a QoQ basis from $28.1 million in Q4 2025.
Prokidney (PROK) Cash from Investing Activities (2021 - 2026) Analysis & Trends
Prokidney (PROK) has 6 years of Cash from Investing Activities data on file, last reported at $34.8 million in Q1 2026.
- On a quarterly basis, Cash from Investing Activities rose 23.11% year-over-year to $34.8 million in Q1 2026; TTM through Mar 2026 was $110.5 million, a 1239.68% increase from a year earlier, with the FY2025 full-year figure at $104.0 million, up 409.28% from the prior year.
- Cash from Investing Activities for Q1 2026 stood at $34.8 million, up from $28.1 million in the prior quarter.
- Over the last five years, Cash from Investing Activities for PROK reached as high as $58.4 million in Q1 2024 and fell as low as -$192.6 million in Q1 2023.
- Historically, Cash from Investing Activities has averaged -$10.1 million across 5 years, with a median of -$207000.0 in 2022.
- Across the five-year window, Cash from Investing Activities plunged 31221.57% in 2023 and surged 317.21% in 2024, its largest moves.
- Year by year, Cash from Investing Activities stood at -$306000.0 in 2022, then plunged by 31221.57% to -$95.8 million in 2023, then surged by 115.73% to $15.1 million in 2024, then soared by 86.29% to $28.1 million in 2025, then gained by 23.97% to $34.8 million in 2026.
- Per Business Quant data, the three most recent Cash from Investing Activities figures were $34.8 million in Q1 2026, $28.1 million in Q4 2025, and $29.0 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Investing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,621.14 Bn | 66,620.85 Bn | - | - |
| 2 | Nanobiotix | 1,915.18 Bn | 1,915.11 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | - |
| 4 | BeOne Medicines | 471.27 Bn | 466.48 Bn | 1.35 Bn | -45.51 Mn |
| 5 | Vertex Pharmaceuticals | 121.81 Bn | 114.57 Bn | 2.59 Bn | -431.90 Mn |
| 6 | Regeneron Pharmaceuticals | 69.58 Bn | 60.82 Bn | 3.31 Bn | -428.90 Mn |
| 7 | Belite Bio | 62.72 Bn | 62.72 Bn | - | - |
| 8 | Argenx Se | 55.51 Bn | 50.33 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.35 Bn | 37.35 Bn | - | 172.62 Mn |
| 10 | Prokidney | 96.00 Mn | 96.00 Mn | - | 34.83 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 34.83 Mn |
| Mar 31, 2026 | 34.83 Mn |
| Dec 31, 2025 | 28.09 Mn |
| Dec 31, 2025 | 28.09 Mn |
| Sep 30, 2025 | 29.02 Mn |
| Sep 30, 2025 | 29.02 Mn |
| Jun 30, 2025 | 18.57 Mn |
| Jun 30, 2025 | 18.57 Mn |
| Mar 31, 2025 | 28.29 Mn |
| Mar 31, 2025 | 28.29 Mn |
| Dec 31, 2024 | 15.08 Mn |
| Dec 31, 2024 | 15.08 Mn |
| Sep 30, 2024 | -81.64 Mn |
| Sep 30, 2024 | -81.64 Mn |
| Jun 30, 2024 | 28.57 Mn |
| Jun 30, 2024 | 28.57 Mn |
| Mar 31, 2024 | 58.40 Mn |
| Mar 31, 2024 | 58.40 Mn |
| Dec 31, 2023 | -95.84 Mn |
| Dec 31, 2023 | -95.84 Mn |